Timing of high dose methotrexate CNS prophylaxis in DLBCL:a multicenter international analysis of 1,384 patients

Autor: Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J. M. Ferreri, Kate Cwynarski, Pamela McKay
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Wilson, M R, Eyre, T A, Kirkwood, A A, Wong Doo, N, Soussain, C, Choquet, S, Martinez-Calle, N, Preston, G, Ahearne, M J, Schorb, E, Moles-Moreau, M-P, Ku, M, Rusconi, C, Khwaja, J, Narkhede, M, Lewis, K L, Calimeri, T, Durot, E, Renaud, L, Øvlisen, A K, Mcilroy, G, Ebsworth, T J, Elliot, J, Santarsieri, A, Ricard, L, Shah, N, Liu, Q, Zayac, A S, Vassallo, F, Lebras, L, Roulin, L, Lombion, N, Manos, K, Fernandez, R, Hamad, N, Lopez-Garcia, A, O'Mahony, D, Gounder, P, Forgeard, N, Lees, C, Agbetiafa, K, Strüessmann, T, Htut, T W, Clavert, A, Scott, H, Guidetti, A, Barlow, B R, Tchernonog, E, Smith, J, Miall, F, Fox, C P, Cheah, C Y, El Galaly, T C, Ferreri, A J M, Cwynarski, K & McKay, P 2022, ' Timing of high dose methotrexate CNS prophylaxis in DLBCL : a multicenter international analysis of 1,384 patients ', Blood, vol. 139, no. 16, pp. 2499-2511 . https://doi.org/10.1182/blood.2021014506
Popis: Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We conducted a retrospective, international analysis of 1384 patients receiving HD-MTX CNS prophylaxis either intercalated (i-HD-MTX) (n = 749) or at the end (n = 635) of R-CHOP/R-CHOP-like therapy (EOT). There were 78 CNS relapses (3-year rate 5.7%), with no difference between i-HD-MTX and EOT: 5.7% vs 5.8%, P = .98; 3-year difference: 0.04% (−2.0% to 3.1%). Conclusions were unchanged on adjusting for baseline prognostic factors or on 6-month landmark analysis (n = 1253). In patients with a high CNS international prognostic index (n = 600), the 3-year CNS relapse rate was 9.1%, with no difference between i-HD-MTX and EOT. On multivariable analysis, increasing age and renal/adrenal involvement were the only independent risk factors for CNS relapse. Concurrent intrathecal prophylaxis was not associated with a reduction in CNS relapse. R-CHOP delays of ≥7 days were significantly increased with i-HD-MTX vs EOT, with 308 of 1573 (19.6%) i-HD-MTX treatments resulting in a delay to subsequent R-CHOP (median 8 days). Increased risk of delay occurred in older patients when delivery was later than day 10 in the R-CHOP cycle. In summary, we found no evidence that EOT delivery increases CNS relapse risk vs i-HD-MTX. Findings in high-risk subgroups were unchanged. Rates of CNS relapse in this HD-MTX-treated cohort were similar to comparable cohorts receiving infrequent CNS prophylaxis. If HD-MTX is still considered for certain high-risk patients, delivery could be deferred until R-CHOP completion.
Databáze: OpenAIRE
Externí odkaz: